Equities

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)114.65
  • Today's Change0.42 / 0.37%
  • Shares traded1.37m
  • 1 Year change+38.35%
  • Beta0.7279
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,6761,9892,116
Total Receivables, Net440260172
Total Inventory323204186
Prepaid expenses303131
Other current assets, total11074100
Total current assets2,5792,5582,604
Property, plant & equipment, net357245237
Goodwill, net------
Intangibles, net307.5814
Long term investments6.533135
Note receivable - long term------
Other long term assets269265246
Total assets3,2653,1283,148
LIABILITIES
Accounts payable1659677
Accrued expenses219353225
Notes payable/short-term debt000
Current portion long-term debt/capital leases105----
Other current liabilities, total164171151
Total current liabilities654620453
Total long term debt1,1331,5441,097
Total debt1,2381,5441,097
Deferred income tax------
Minority interest------
Other liabilities, total619580670
Total liabilities2,4052,7432,220
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital5,3054,2974,135
Retained earnings (accumulated deficit)(4446)(3910)(3207)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.92(1.66)(0.02)
Total equity859385928
Total liabilities & shareholders' equity3,2653,1283,148
Total common shares outstanding948887
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.